Answers are grounded in this paper and cite their sources.
Randomized trial shows tranexamic acid reduces blood loss and transfusion requirements in patients, suggesting a safer surgical approach.
Background: Major lower limb orthopaedic surgeries are associated with significant perioperative blood loss and a high requirement for allogeneic blood transfusion, which carries risks and increases healthcare burden. Tranexamic acid (TA), an antifibrinolytic agent, has been proposed to reduce bleeding and transfusion needs. Aim: To assess the efficacy and safety of tranexamic acid in reducing postoperative blood loss and transfusion requirements in patients undergoing lower limb orthopaedic surgeries. Methods: Ninety ASAI & II patients scheduled for elective femoral fracture surgeries were randomized to receive either intravenous TA (10 mg/kg) or placebo (normal saline) 15 minutes before incision. Postoperative blood loss, haemoglobin levels, transfusion requirements, and complications were recorded. Results: TA significantly reduced postoperative blood loss (mean drain volume: 39.33± vs 91.11± mL, P=0.01), fall in haemoglobin (day 0: 2.99±3.46 vs 7.70±6.05 g/dL, P=0.01; day 2: 0.4±0.74 vs 2.71±2.70 g/dL, P=0.000), and transfusion rates (7/45 vs 18/45, P=0.01) compared to placebo. No significant increase in thromboembolic events was observed. Conclusion: Preoperative administration of tranexamic acid significantly reduces blood loss and transfusion requirements in lower limb orthopaedic surgeries without increasing thromboembolic complications1.
No takes yet. Share an insight, caveat, or question.
Shrivastava et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: